1-Amino-5-bromouracilAlternative Names: ABU
Latest Information Update: 16 Jun 1996
At a glance
- Originator Yamasa Corporation
- Class Anxiolytics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Anxiety disorders
Most Recent Events
- 16 Jun 1996 Discontinued-Preclinical for Anxiety disorders in Japan (Unknown route)